AndreaBozzo/ceres-open-data-index huggingface dataset:
COVID-19 State Profile Report - Pennsylvania

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
A prospective, cross-sectional study of anaemia and peripheral iron status in antiretroviral naïve, HIV-1 infected children in Cape Town, South Africa

Background
          Anaemia is a common manifestation of paediatric HIV infection. Although there are many causes, anaemia of chronic diseases is the most frequent type. In poor countries iron deficiency is widespread. It is probable that many HIV-infected children in these countries are also iron deficient. This study describes the relationship between paediatric HIV infection and anaemia, and documents the peripheral iron status of antiretroviral naive, HIV-infected children.
        
        
          Methods
          Sixty children were evaluated prospectively. Investigations included CD4+ count, haemoglobin concentration (Hb), red blood cell (RBC) morphology, and iron studies.
        
        
          Results
          Anaemia was present in 73% of children. Compared to mild HIV infection, median Hb was lower in children with moderate clinical infection (104 g/L v 112 g/L, p = 0.04) and severe clinical infection (96 g/L v 112 g/L, p = 0.006), and more children with severe infection were anaemic (92% v 58%, 0.04). There was a significant relationship between immunological status and Hb. 68% had abnormal RBC morphology. Significantly more children with moderate and severe disease, and severe immunosuppression had abnormal RBC morphology. 52% were iron-depleted, 20% had iron-deficient erythropoiesis and 18% iron deficiency anaemia (IDA). 16% (7/44) of anaemic children had microcytosis and hypochromia. Median soluble transferrin receptor concentration was significantly higher in those with microcytic hypochromic anaemia (42.0 nmol/L v 30.0 nmol/L, p = 0.008).
        
        
          Conclusions
          Both the proportion of anaemic children and the median Hb were associated with disease status. Iron depletion and IDA are major problems in HIV-infected children in South Africa.
NNDSS - TABLE 1J. Dengue virus infections, Dengue to Severe dengue

NNDSS - TABLE 1J. Dengue virus infections, Dengue to Severe dengue - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes: 
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). 
§ Includes data for dengue and dengue-like illness.
Compound 526582: 2,10,22-Trimethyldotriacontane

Chemical compound data from PubChem database. IUPAC Name: 2,6,22-trimethyldotriacontane. Molecular Formula: C35H72. Molecular Weight: 492.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2011 CMHS Uniform Reporting System (URS) Output Tables for Montana

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 528301: Pyrazine, 2-decyl-3-methoxy

Chemical compound data from PubChem database. IUPAC Name: 2-decyl-3-methoxypyrazine. Molecular Formula: C15H26N2O. Molecular Weight: 250.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530574: 2,6-Difluorobenzoic acid, hexyl ester

Chemical compound data from PubChem database. IUPAC Name: hexyl 2,6-difluorobenzoate. Molecular Formula: C13H16F2O2. Molecular Weight: 242.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399672-T1: [Translated] DEVICE AND METHOD FOR CONTROLLING THE WHEEL TORQUE OF A VEHICLE

A motor vehicle power train control device capable of furnishing set signals of torque applied to wheels of the motor vehicle. The control device includes a mechanism to generate a signal representing a limitation of variation in speed of a heat engine integrated in a power train capable of reducing variations that are disturbing with regard to acoustics of the power train, and includes a mechanism to determine an operating point of the power train in an optimal operating range according to the signal that represents limitation of speed. The mechanism for generating the signal that represents a limitation of variation in the speed of the heat engine integrated in the power train is furnished, at an input, by parameters that represent characteristics of the motor vehicle and by parameters that represent the driver's wishes.
Compound 527589: 2-Propyn-1-ol, tribromoacetate

Chemical compound data from PubChem database. IUPAC Name: prop-2-ynyl 2,2,2-tribromoacetate. Molecular Formula: C5H3Br3O2. Molecular Weight: 334.79. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Novel memory mutants in

Background
          Starting from Benzer's initiative, the approach of forward genetics has been widely used to isolate mutations affecting learning and memory. For this aim, mainly the odor-shock conditioning was employed. We have isolated P insertional mutations affecting memory after courtship conditioning – another form of classical conditioning in Drosophila. Here we report the behavioral characteristics of one of these mutants, which we have called nemy (no extended memory).
        
        
          Results
          The courtship activity of Drosophila males is reduced when a male has a previous experience of courting a fertilized female. In the wild-type strain C-S (K), this conditioned courtship inhibition lasts for 1–3 h in the test with a virgin female, and at least for 8 h in the test with a subsequent fertilized female. The mutant males nemyP153 display distinct memory deficiency in both tests already 0.5 h after training. The mutant males show an increased level of locomotor activity unrelated to courtship, and spend more time in such an element of courtship as pursuit. This, however, seems to be a pleiotropic effect of the mutation, independent from its influence on the courtship conditioning. The mutation reduces also memory performance after the odor-shock classical conditioning. At the same time, the sensory and motor functions involved in this type of learning seem to be normal.
        
        
          Conclusions
          Insertion of P-lacW vector into 49B region of the second chromosome (mutation nemyP153) causes an increased level of locomotor activity, memory deficiency after the courtship conditioning and subnormal acquisition after the odor-shock conditioning.
Patent AT-E400291-T1: [Translated] A SUSPENSION FORMULATION CONTAINING BIOMOLECULES OF INCREASED STABILITY - RELEASABLE VIA AN IMPLANTABLE AID

Chemical patent from PubChem database. Patent Number: AT-E400291-T1. Title: Pharmaceutical Salt Forms. Filing Date: 2013-05-24. Inventors: Yamamoto, Hiroshi, Schmidt, Hans. Abstract: Novel pharmaceutical salt forms are provided, exhibiting improved physicochemical properties including enhanced solubility, stability, and bioavailabi... IPC Classifications: C08G, C08K, A61K. This patent covers 21 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 528455: 1-Octadecene, 4,9,13,17-tetramethyl

Chemical compound data from PubChem database. IUPAC Name: 4,9,13,17-tetramethyloctadec-1-ene. Molecular Formula: C22H44. Molecular Weight: 308.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Treatment Episode Data Set (TEDS): 2015, National Discharge from Substance Abuse Treatment Services

This report presents data from the Treatment Episode Data Set (TEDS) for discharges from treatment in 2015. It is a companion to the reports Treatment Episode Data Set (TEDS): 2005-2015 National Admissions to Substance Abuse Treatment and Treatment Episode Data Set (TEDS): 2005-2015 State Admissions to Substance Abuse Treatment. These reports provide information on the demographic and substance abuse characteristics of substance abuse treatment admissions and discharges aged 12 and older in facilities that report to individual state administrative data systems. In addition, characteristics used to analyze changes from admission to discharge among the linked admission and discharge records are included. Primary substance of abuse, frequency of use, and employment status at admission are repeated in several tables. This is done so that characteristics at admission and discharge can be appropriately compared with each other and to ensure the inclusion of important data that might otherwise be overlooked.
Trend Tables (Standard Errors and P Values) - 7.1 to 7.45

These detailed tables show standard errors for trends in totals and prevalence estimates of illicit drug use, risk and protective factors, substance initiation, substance dependence/abuse, and need/receipt of substance use treatment from the 2011 National Survey on Drug Use and Health (NSDUH). Substances examined include illicit drugs (e.g., marijuana, cocaine, heroin, hallucinogens (including LSD, PCP, Ecstasy, Ketamine, DMT/AMT/Foxy, Salvia divinorum), inhalants, and the nonmedical use of prescription-type pain relievers (including OxyContin), tranquilizers, stimulants (Adderall), sedatives (GHB, Ambien), non-prescription cold medicine, alcohol, and tobacco products (including cigarettes, smokeless tobacco, cigars, pipes). Standard errors are provided for totals and estimates of lifetime, past year, and past month use by age group, gender, race/ethnicity, education level, employment status, and geographic area.
Frailty, fitness and late-life mortality in relation to chronological and biological age

Background
          People age at remarkably different rates, but how to estimate trajectories of senescence is controversial.
        
        
          Methods
          In a secondary analysis of a representative cohort of Canadians aged 65 and over (n = 2914) we estimated a frailty index based on the proportion of 20 deficits observed in a structured clinical examination. The construct validity of the index was examined through its relationship to chronological age (CA). The criterion validity was examined in its ability to predict mortality, and in relation to other predictions about aging. From the frailty index, relative (to CA) fitness and frailty were estimated, as was an individual's biological age.
        
        
          Results
          The average value of the frailty index increased with age in a log-linear relationship (r = 0.91; p < 0.001). In a Cox regression analysis, biological age was significantly more highly associated with death than chronological age. The average increase in the frailty index (i.e. the average accumulation of deficits) amongst those with no cognitive impairment was 3 per cent per year.
        
        
          Conclusions
          The frailty index is a sensitive predictor of survival. As the index includes items not traditionally related to adverse health outcomes, the finding is compatible with a view of frailty as the failure to integrate the complex responses required to maintain function.
A simple method for serving Web hypermaps with dynamic database drill-down

Background
          HealthCyberMap  aims at mapping parts of health information cyberspace in novel ways to deliver a semantically superior user experience. This is achieved through "intelligent" categorisation and interactive hypermedia visualisation of health resources using metadata, clinical codes and GIS. HealthCyberMap is an ArcView 3.1 project. WebView, the Internet extension to ArcView, publishes HealthCyberMap ArcView Views as Web client-side imagemaps. The basic WebView set-up does not support any GIS database connection, and published Web maps become disconnected from the original project. A dedicated Internet map server would be the best way to serve HealthCyberMap database-driven interactive Web maps, but is an expensive and complex solution to acquire, run and maintain. This paper describes HealthCyberMap simple, low-cost method for "patching" WebView to serve hypermaps with dynamic database drill-down functionality on the Web.
        
        
          Results
          The proposed solution is currently used for publishing HealthCyberMap GIS-generated navigational information maps on the Web while maintaining their links with the underlying resource metadata base.
        
        
          Conclusion
          The authors believe their map serving approach as adopted in HealthCyberMap has been very successful, especially in cases when only map attribute data change without a corresponding effect on map appearance. It should be also possible to use the same solution to publish other interactive GIS-driven maps on the Web, e.g., maps of real world health problems.
Compound 525339: 1,1,3-Tris(methylthio)propane

Chemical compound data from PubChem database. IUPAC Name: 1,1,3-tris(methylsulfanyl)propane. Molecular Formula: C6H14S3. Molecular Weight: 182.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527720: Isopropyl 3-bromopropanoate

Chemical compound data from PubChem database. IUPAC Name: propan-2-yl 3-bromopropanoate. Molecular Formula: C6H11BrO2. Molecular Weight: 195.05. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401622-T1: [Translated] METHOD FOR CHECKING THE INTEGRITY OF MANY INDIVIDUAL PACKAGES

A process for integrity check of lots of individual package units which comprises combining at least one RFID tag and a container which contains a large number of individual package units wherein each of the individual package units is marked with a marking code, the information of these codes of all individual package units is combined, and a hash code is generated based on the combined information of all marking codes of all individual package units, which combined hash code is stored in an RFID tag which is affixed to the container, this combined hash code together with the individual hash codes for the individual package units being stored in the data base of the SENDER site where the container is packed and sealed, the individual hash codes then being transmitted to the RECIPIENT of the said container, the information collected from the RFID tag being compared to the combined hash code which is calculated at the RECIPIENT site from the information received by the SENDER of the said container including all individual hash codes of all package units in the said container, and to the combined hash code calculated from the markings on the individual package units or boxes scanned at the RECIPIENT site, and the application of the said process in the verification of the integrity of pharmaceutical goods, video information such as movies on DVD, audio information such as music on CD, computer files, or paper documents
Patent AT-E400381-T1: [Translated] METHOD FOR INCREASE THE LIFESPAN OF THE WIDE SIDE WALLS OF AN ADJUSTABLE MOLD

The invention relates to a method for prolonging the serviceable life of the broad side walls of a mold, which is formed from broad side walls and narrow side walls, in a continuous casting installation for continuously casting a metal casting. In order to significantly prolong the serviceable life of a mold, in particular, for casting long sequences with the same casting width, the invention provides that a casting center axis (11, 11<sub
Preliminary Findings from Drug-Related Emergency Department Visits, 2021

Preliminary Findings from Drug-Related Emergency Department Visits, 2021. An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP22-07-03-001.pdf
Impaired Driving Death Rate, by Age and Sex, 2012 & 2014, Region 4 - Atlanta

Rate of deaths by age/gender (per 100,000 population) for people killed in crashes involving a driver with BAC =>0.08%, 2012, 2014. 2012 Source: Fatality Analysis Reporting System (FARS). 2014 Source: National Highway Traffic Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2014 Annual Report File. Note: Blank cells indicate data are suppressed. Fatality rates based on fewer than 20 deaths are suppressed.
Mouse ribonuclease III. cDNA structure, expression analysis, and chromosomal location

Background
          Members of the ribonuclease III superfamily of double-stranded(ds)-RNA-specific endoribonucleases participate in diverse RNA maturation and decay pathways in eukaryotic and prokaryotic cells. A human RNase III orthologue has been implicated in ribosomal RNA maturation. To better understand the structure and mechanism of mammalian RNase III and its involvement in RNA metabolism we determined the cDNA structure, chromosomal location, and expression patterns of mouse RNase III.
        
        
          Results
          The predicted mouse RNase III polypeptide contains 1373 amino acids (~160 kDa). The polypeptide exhibits a single C-terminal dsRNA-binding motif (dsRBM), tandem catalytic domains, a proline-rich region (PRR) and an RS domain. Northern analysis and RT-PCR reveal that the transcript (4487 nt) is expressed in all tissues examined, including extraembryonic tissues and the midgestation embryo. Northern analysis indicates the presence of an additional, shorter form of the transcript in testicular tissue. Fluorescent in situ hybridization demonstrates that the mouse RNase III gene maps to chromosome 15, region B, and that the human RNase III gene maps to a syntenic location on chromosome 5p13-p14.
        
        
          Conclusions
          The broad transcript expression pattern indicates a conserved cellular role(s) for mouse RNase III. The putative polypeptide is highly similar to human RNase III (99% amino acid sequence identity for the two catalytic domains and dsRBM), but is distinct from other eukaryotic orthologues, including Dicer, which is involved in RNA interference. The mouse RNase III gene has a chromosomal location distinct from the Dicer gene.